Taken together, these observations are consistent with a view that O-GlcNAcylation may sustain cancer cells and that blocking OGT and the hexosamine pathway offers a novel approach to treatment for many cancers including CLL. Here, OGT is linked to B-cell chronic lymphocytic leukemia.